1. INTRODUCTION
===============

Implementation of new chemotherapy protocols at the BC Cancer Agency ([bcca]{.smallcaps}) is subject to approval by the Priorities and Evaluation Committee ([pec]{.smallcaps}) and the Systemic Therapy Program ([stp]{.smallcaps}). Reports of the effectiveness of new therapies in journals and conference proceedings lead to their evaluation by [bcca]{.smallcaps} tumour groups, whose members advance appropriate protocols to [pec]{.smallcaps} for approval and to [stp]{.smallcaps} for funding. Normally, phase [iii]{.smallcaps} clinical trial data with adequate follow-up---or meta-analyses---are required to support major new programs. For less common malignancies, only phase [ii]{.smallcaps} data may be available. In the period between the results of phase [ii]{.smallcaps} and [iii]{.smallcaps} trials, or before [pec]{.smallcaps} and [stp]{.smallcaps} approval, utilization of evolving therapies may be requested through the Compassionate Access Program ([cap]{.smallcaps}).

Esophagogastric adenocarcinoma treatment has progressed in the past decade to include adjuvant and primary chemoradiotherapy for esophageal cancer [@b1-co16-5-9],[@b2-co16-5-9] and postoperative chemoradiotherapy for gastroesophageal junction and gastric adenocarcinomas [@b3-co16-5-9]. These results led to the introduction at [bcca]{.smallcaps} of [giefuprt]{.smallcaps} \[cisplatin, infusional 5-fluorouracil (5[fu]{.smallcaps}), radiation therapy\] and [gigairt]{.smallcaps} (5-fluorouracil, folinic acid, and radiation therapy) regimens for esophageal and gastric cancers respectively [@b4-co16-5-9],[@b5-co16-5-9] ([Table I](#tI-co16-5-9){ref-type="table"}). For incurable metastatic esophagogastric adenocarcinoma, the [bcca]{.smallcaps} Gastro-intestinal Tumour Group supports one standard-of-care ([soc]{.smallcaps}) chemotherapy regimen incorporating weekly infusional 5[fu]{.smallcaps} and cisplatin ([gifuc]{.smallcaps} [@b6-co16-5-9],[@b7-co16-5-9]). All other regimens require [cap]{.smallcaps} approval for public funding. The present report describes the [bcca]{.smallcaps} experience with various regimens for metastatic esophagogastric adenocarcinoma in the second line after [soc]{.smallcaps} chemotherapy ([cap]{.smallcaps}2), or in the first line instead of [soc]{.smallcaps} ([cap]{.smallcaps}1). The principal objective of this type of practice review is to assist future treatment decision-making by assessing the total provincial patient experience, which would otherwise be unknown to individual physicians.

2. PATIENTS AND METHODS
=======================

This retrospective review was approved by the Research Ethics Board of the [bcca]{.smallcaps} and University of British Columbia. It includes patients with surgically incurable esophagogastric adenocarcinoma who received a chemotherapy regimen through the [cap]{.smallcaps} either as initial therapy ([cap]{.smallcaps}1) or in the second line ([cap]{.smallcaps}2) after the current [soc]{.smallcaps} regimen of cisplatin and infusional 5[fu]{.smallcaps} [@b6-co16-5-9],[@b7-co16-5-9]. Patients were identified from the database of the [bcca cap]{.smallcaps}, which approves funding and collects data prospectively on these patients. The [bcca]{.smallcaps} clinical records and local hospital records were retrieved, and the relevant clinical and pathology information was abstracted into a separate database for analysis. The time period was 77 months from December 1, 1999, through April 30, 2006.

Database fields included date of birth and sex; disease stage at diagnosis, primary site, and date of diagnosis; prior surgical, radiotherapy, and adjuvant chemotherapy status; initial and subsequent chemotherapy regimen or regimens; start and finish dates for chemotherapy; worst toxicity grade and type recorded; number of hospital days attributable to chemotherapy complications; response category if documented; date of last follow-up and patient status at that time. Overall survival was defined as time from diagnosis until death from any cause, calculated using the Kaplan--Meier method [@b8-co16-5-9]. Data were analyzed using the Statistical Software Package for the Social Sciences (SPSS, version 10.1 for Windows: SPSS, Chicago, IL, U.S.A.).

3. RESULTS
==========

A total of 85 patients \[61 men (72%), 24 women; 68 Caucasian, 15 Asian, 2 Fijian; median age: 56.2 years (range: 28.7--81.8 years)\] received [cap]{.smallcaps} chemotherapy regimens for esophagogastric adenocarcinoma ([Table II](#tII-co16-5-9){ref-type="table"}). Disease stage was M1 in 55 patients at diagnosis. The primary tumours were gastric (*n* = 53) and esophageal (*n* = 32), with 10 gastroesophageal junction tumours in the latter group. Prior therapies included radical surgery (*n* = 34), chemoradiotherapy (*n* = 14), and adjuvant chemotherapy (*n* = 3). Of the patients who received [cap]{.smallcaps}1 chemotherapy (*n* = 50), 25, 9, and 2 received second-, third-, and fourth-line chemotherapy respectively. Reasons for using [cap]{.smallcaps}1 included failure of prior adjuvant therapy \[*n* = 13: [folfiri]{.smallcaps} (5[fu]{.smallcaps}, irinotecan, leucovorin), 5; [dcf]{.smallcaps} (docetaxel, cisplatin, 5[fu]{.smallcaps}), 3; other regimens, 5\], physician preference \[*n* = 22: [dcf]{.smallcaps}, 8; [folfiri]{.smallcaps}, 8; [giefup]{.smallcaps} (cisplatin, infusional 5[fu]{.smallcaps}, with or without radiation therapy), 6, of whom 2 received concomitant radiation therapy\], and patients unsuitable for, or declining, cisplatin or infusional 5[fu]{.smallcaps} (*n* = 15). There was a trend toward younger age patients receiving [cap]{.smallcaps}1 chemotherapy (median age: 55.3 years vs. 60.3 years). In 35 patients, [soc]{.smallcaps} was followed by [cap]{.smallcaps}2 chemotherapy. Docetaxel and irinotecan regimens accounted for 34% and 36%, 5% and 55%, and 16% and 32% of first-, second-, and third-line [cap]{.smallcaps} chemotherapy regimens respectively.

The proportions of patients experiencing grade 3 or 4 toxicity with [soc]{.smallcaps} chemotherapy and with [cap]{.smallcaps}1 chemotherapy were 5/35 (17%) and 19/50 (39%) respectively. There were 20 hospitalizations attributable to [cap]{.smallcaps}1 or [cap]{.smallcaps}2, and 2 attributable to [soc]{.smallcaps} chemotherapy. Toxicity caused 1 death ([folfiri]{.smallcaps} regimen). Partial responses were seen with [soc]{.smallcaps} (11/35) and [cap]{.smallcaps}1 (6/50) chemotherapy. Second-line chemotherapy produced 4 responses: 2 after failing [soc]{.smallcaps}, and 2 after failing [cap]{.smallcaps}1. Median follow-up was 8.9 months.

Median survival time for all patients was 9.7 months \[95% confidence interval ([ci]{.smallcaps}): 6.2 to 13.1 months\]. [Figures 1](#f1-co16-5-9){ref-type="fig"} and [2](#f2-co16-5-9){ref-type="fig"} present survival analyses according to primary site and [cap]{.smallcaps}1 or [cap]{.smallcaps}2 chemotherapy. Median survival for patients who had received no prior chemotherapy (*n* = 68) was 11.6 months (95% [ci]{.smallcaps}: 8.4 to 14.9 months); for those who had received prior chemotherapy, it was 5.2 months (95% [ci]{.smallcaps}: 2.4 to 7.9 months). Median survival for patients over 50 years of age at diagnosis (11.6 months) was longer than that for patients under 50 years of age (6.6 months).

4. DISCUSSION
=============

New chemotherapy regimens have been extensively studied in esophageal and gastric adenocarcinomas [@b9-co16-5-9]--[@b14-co16-5-9]. Improvements in survival have been demonstrated in phase [iii]{.smallcaps} trials in gastric cancer, but only phase [ii]{.smallcaps} trials have been undertaken in metastatic esophageal cancer, mainly because of small numbers of suitable patients. Patients with gastroesophageal junction cancer are sometimes included in gastric cancer trials on the assumption that those diseases are biologically similar. With the increasing use of adjuvant regimens in esophagogastric cancer, more patients with advanced disease have been previously exposed to at least a fluoropyrimidine.

Debate continues in North America about the relative merits of newer regimens in metastatic esophagogastric cancer, especially when survival differences are small and toxicity rates are equal or greater [@b15-co16-5-9],[@b16-co16-5-9]. For example, as compared with [cf]{.smallcaps} (cisplatin, 5[fu]{.smallcaps}) in advanced gastric cancer, [dcf]{.smallcaps} yields a longer median survival (9.2 months vs. 8.6 months) and a better 2-year survival rate (18% vs. 9%), which led to its approval by the U.S. Food and Drug Administration for gastric and gastroesophageal junction cancers [@b9-co16-5-9]. Grades 3 and 4 non-hematologic and neutropenic toxicity rates were 81% and 84% respectively with [dcf]{.smallcaps} [@b9-co16-5-9]. The editorial that accompanied publication ("Does the punishment fit the crime?") reflects the balance required between survival gains and toxicities experienced [@b17-co16-5-9]. Overall survival after [ecf]{.smallcaps} (epirubicin, cisplatin, 5[fu]{.smallcaps}) chemotherapy was longer than that with [famtx]{.smallcaps} (doxorubicin, 5[fu]{.smallcaps}, leucovorin, methotrexate: 8.9 months vs. 5.7 months) at the cost of more nausea, vomiting, and alopecia, and fewer episodes of neutropenia and infection [@b10-co16-5-9]. Survival after [folfiri]{.smallcaps} was equivalent to that after [cf]{.smallcaps}, but more grade 3+ diarrhea occurred with [folfiri]{.smallcaps} (22% vs. 7%) and more grade 3 neutropenia occurred with [cf]{.smallcaps} (52% vs. 25%) [@b12-co16-5-9]. There is no standard second-line chemotherapy regimen for gastric cancer after failure of either adjuvant or first-line chemotherapy [@b16-co16-5-9].

In metastatic esophageal cancer, chemotherapy is usually limited to patients with a good performance status (Eastern Cooperative Oncology Group ≤ 2), preferably in a clinical trial. A regimen of cisplatin--5[fu]{.smallcaps} has been used most frequently. Other regimens include [ecf]{.smallcaps}, irinotecan--cisplatin, paclitaxel--[cf]{.smallcaps}, paclitaxel--carboplatin, gemcitabine--cisplatin, [folfiri]{.smallcaps}, and capecitabine (in place of 5[fu]{.smallcaps})--oxaliplatin. Two regimens are the recommended maximum, because of a lack of a proven survival benefit. Regimen choice depends in part on prior chemotherapy received, organ function status (especially renal status), and issues of venous access [@b15-co16-5-9].

Integration of new or nonstandard chemotherapy regimens into clinical practice occurs in response to evolving clinical trial results, adequate levels of evidence, and availability of drugs with differing modes of action and toxicity profiles. Typically, the institutional process for approval of a new regimen or indication takes several months, during which time [cap]{.smallcaps} access may be available. Physicians may apply to use a novel regimen in the first line if there are any clinical contraindications to the current [bcca soc]{.smallcaps}. However, many regimens shown to be active in phase [ii]{.smallcaps} trials are not advanced to full systemic therapy approval because of infrequent usage.

Our experience with the use of nonstandard regimens in the first line ([cap]{.smallcaps}1) in metastatic esophagogastric cancer is reported in conjunction with that in patients on [soc]{.smallcaps} who later receive [cap]{.smallcaps} regimens ([cap]{.smallcaps}2). Both groups of patients are inevitably "selected" in terms of reasons for [cap]{.smallcaps}1 use---for example, better performance status in some cases ([dcf]{.smallcaps} regimen), diminished organ function (for example, favouring irinotecan regimens over cisplatin in the presence of renal dysfunction), or failure of prior adjuvant therapy or radical chemoradiotherapy. Furthermore, patients were all deemed sufficiently fit to receive both [cap]{.smallcaps}1 and [cap]{.smallcaps}2 regimens. Notably, only 50% of [cap]{.smallcaps}1 patients received secondary therapies; by definition, all [cap]{.smallcaps}2 patients had received [soc]{.smallcaps} therapy first. Hence there is potential bias in both directions.

Response assessments in retrospective analyses such as the present one are problematic, because they are not protocol-mandated and are subjective in terms of symptom and palliative benefit. Unlike the 20% seen in the present series, few or no patients had received prior chemotherapy in most published trials ([Table III](#tIII-co16-5-9){ref-type="table"}). The hard endpoint is survival, and the observed survival time (median: 9.7 months) and proportion (10.4% at 2 years) in the present series are consistent with contemporary clinical trials. Median survival after [gifuc]{.smallcaps} chemotherapy in 205 patients across British Columbia between 2001 and 2006, 25% of whom received second-line or subsequent chemotherapy, was 11.2 months [@b18-co16-5-9]. Conservatively interpreted, this survival appears to be at least as good as the median survival for all patients in the present series (9.7 months) and for those who received [cap]{.smallcaps}1 chemotherapy (7.5 months).

An examination of toxicity rates between [soc]{.smallcaps} and [cap]{.smallcaps}1 patients is subject to less potential bias. Despite patients being selected as suitable for [cap]{.smallcaps} therapies, severe toxicity and hospitalization rates were higher with [cap]{.smallcaps}1 therapy. Although the negative resource and quality-of-life impacts of these events are self-explanatory, they may have affected survival either positively or negatively. Severity of side effects of chemotherapy has been associated with higher response rates and longer survival in advanced colorectal cancer [@b19-co16-5-9]. However, until this association is proven prospectively in esophagogastric cancer, the merits of first-line therapy with other than fluorouracil--cisplatin should be carefully considered in view of the toxicity encountered.

5. CONCLUSIONS
==============

The use of nonstandard chemotherapy regimens for surgically incurable esophagogastric adenocarcinoma in British Columbia has been examined and outcomes have been analysed. To put their own experiences into perspective, individual physicians need population outcome analyses of the kind that this review provides. Caution is, of course, required in interpreting retrospective nonrandomized patient cohorts. Nevertheless, nonstandard chemotherapy regimens have substantial toxicities that should be discussed with patients as part of the decision process in their use.
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###### 

BC Cancer Agency esophagogastric cancer protocols

  Protocol                 5-Fluorouracil                            Cisplatin                Folinic acid                  Cycle
  ------------------------ ----------------------------------------- ------------------------ ----------------------------- ---------
  [gifuc]{.smallcaps}      1000 mg/m^2^ infusion, daily for 2 days   25 mg/m^2^ once, day 1   ---                           7 days
  [giefuprt]{.smallcaps}   1000 mg/m^2^ infusion, daily for 4 days   25 mg/m^2^ for 3 days    ---                           28 days
  [gigairt]{.smallcaps}    425 mg/m^2^ bolus, daily for 5 days                                20 mg/m^2^ daily for 5 days   28 days

###### 

Patient characteristics by Compassionate access Program ([cap]{.smallcaps}) usage

                                         Pts (*n*)   Men \[*n* (%)\]   Median age (years)   Prior chemotherapy \[*n* (%)\]   M1 at diagnosis \[*n* (%)\]
  -------------------------------------- ----------- ----------------- -------------------- -------------------------------- -----------------------------
  [cap]{.smallcaps}1                     50          38 (76)           55.3                 16 (32)                          29 (58)
  [soc]{.smallcaps}/[cap]{.smallcaps}2   35          23 (66)           60.4                 1 (3)                            27 (77)

Pts = patients; [cap]{.smallcaps}1 = [cap]{.smallcaps} used in the first line; [soc]{.smallcaps} = standard of care; [cap]{.smallcaps}2 = [cap]{.smallcaps} used in the second line.

###### 

Clinical trial results of chemotherapy in metastatic esophagogastric cancer

  Reference                                 Regimen                 Site              Pts (n)   Prior chemotherapy   Median survival (months)   95% [ci]{.smallcaps}   2-Year survival (%)   Quality of life                                            [trm]{.smallcaps} (%)   Adenocarcinoma (%)
  ----------------------------------------- ----------------------- ----------------- --------- -------------------- -------------------------- ---------------------- --------------------- ---------------------------------------------------------- ----------------------- --------------------
  Webb *et al.,* 1997[@b10-co16-5-9]        [ecf]{.smallcaps}       Esophagogastric   111       No                   8.9                        [nr]{.smallcaps}       11                    [ecf]{.smallcaps}\>[famtx]{.smallcaps}                     0.9                     100
                                            [famtx]{.smallcaps}                       108       No                   5.7                        [nr]{.smallcaps}       6                                                                                1.9                     
  Ross *et al.,* 2002[@b11-co16-5-9]        [ecf]{.smallcaps}       Esophagogastric   289       No                   9.4                        [nr]{.smallcaps}       15.8                  [ecf]{.smallcaps}\>[mcf]{.smallcaps}                       0.3                     93.1
                                            [mcf]{.smallcaps}                         285       No                   8.7                        [nr]{.smallcaps}       14.2                                                                             0.4                     93.0
  Pozzo *et al.,* 2004[@b14-co16-5-9]       [folfiri]{.smallcaps}   Gastric           59        5.4%                 10.7                       8 to 14.6              13                    [folfiri]{.smallcaps}\>[iri]{.smallcaps}+[c]{.smallcaps}   0                       100
  Dank *et al.,* 2005[@b12-co16-5-9]        [folfiri]{.smallcaps}   Esophagogastric   170       Permitted            9                          8.3 to 10.2            14                    Trend favouring [folfiri]{.smallcaps}                      0.6                     100
                                            [cf]{.smallcaps}                          163                            8.7                        7.8 to 9.8             12                                                                               3                       
  Roth *et al.,* 2005[@b13-co16-5-9]        [dcf]{.smallcaps}       Gastric           41        No                   10.4                       8.3 to 12              [nr]{.smallcaps}      [ecf]{.smallcaps}\>[dcf]{.smallcaps}                       0                       100
                                            [ecf]{.smallcaps}                         40        No                   8.3                        7.2 to 13              [nr]{.smallcaps}                                                                 0                       
  Van Cutsem *et al.,* 2006[@b9-co16-5-9]   [dcf]{.smallcaps}       Gastric           221       No                   9.2                        8.4 to 10.6            18                    [dcf]{.smallcaps}\>[cf]{.smallcaps}                        2.7                     100
                                            [cf]{.smallcaps}                          224                            8.6                        7.2 to 9.5             9                                                                                4.5                     
  BC Cancer Agency, this report                                     Esophagogastric   85        20.00%               9.7                        6.2 to 13.1            10.4                  [nr]{.smallcaps}                                           1.2                     100

Pts = patients; [ci]{.smallcaps} = confidence interval; [trm]{.smallcaps} = treatment-related mortality; [ecf]{.smallcaps} = epirubicin, cisplatin, 5-fluorouracil; [famtx]{.smallcaps} = doxorubicin, 5-fluorouracil, leucovorin, methotrexate; [nr]{.smallcaps} = not reported; [mcf]{.smallcaps} = mitomycin, cisplatin, 5-fluorouracil; [folfiri]{.smallcaps} = 5-fluorouracil, irinotecan, leucovorin; [iri]{.smallcaps}+[c]{.smallcaps}= irinotecan + cisplatin; [cf]{.smallcaps}= cisplatin, 5-fluorouracil; [dcf]{.smallcaps}= docetaxel, cisplatin, 5-fluorouracil.
